Anglo-Swedish drug maker AstraZeneca plc (AZN, AZN.L) reported that the data from the final updated overall survival or OS analysis of CONFIRM showed that fulvestrant 500 mg was associated with a 4.1-month improvement in median OS and a 19% relative reduction in the risk of death compared with fulvestrant 250 mg. The median OS for FASLODEX 500 mg and 250 mg was 26.4 months and 22.3 months, respectively.
FASLODEX 500 mg is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
FASLODEX 500 mg increased progression-free survival, the primary end point in CONFIRM, with a relative risk reduction of 20% compared with FASLODEX 250 mg. Median progression free survival with FASLODEX 500 mg was discovered to be 6.5 months, versus 5.5 months with FASLODEX 250 mg.
For comments and feedback: editorial@rttnews.com